Skip to main navigation
Skip to search
Skip to main content
UM Impact Home
Help & FAQ
Home
Profiles
Research units
Publications and Performances
Projects
Prizes
Engagement
Search by expertise, name or affiliation
Natalizumab update: a story of benefit and risk
Laurie J. Barten
, Douglas R. Allington
,
Kendra A. Procacci
, Michael P. Rivey
Pharmacy Practice
University of Montana
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Natalizumab update: a story of benefit and risk'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Natalizumab
100%
Multiple Sclerosis
37%
Crohn's Disease
37%
Progressive Multifocal Leukoencephalopathy
25%
Clinical Trial
12%
Immunosuppressive Agent
12%
Recurrence Risk
12%
Adverse Event
12%
Glatiramer
12%
Beta1a Interferon
12%
Inflammation
12%
Monotherapy
12%
Monoclonal Antibody
12%
Neuroscience
Natalizumab
100%
Multiple Sclerosis
25%
Progressive Multifocal Leukoencephalopathy
25%
Adverse Effect
12%
Monoclonal Antibody
12%
Treatment of Multiple Sclerosis
12%
Antibody Production
12%
Rebound Effect
12%
Interferon Beta 1a
12%
Leukocyte
12%
Immunosuppressive Drug
12%
Glatiramer Acetate
12%